Mike Brandner Now Accepting Cases for Essure Implant Injuries

Mike Brandner Injury Attorneys

Mike Brandner Injury Attorneys are now accepting claims against Essure birth control implants and the serious side effects resulting from the device.

Pharmaceutical giants like Bayer are notorious for being extremely resistant to compensating those their products have injured. Our team wants to help you get the justice you deserve.”

— Mike Brandner

NEW ORLEANS, LOUISIANA , US, August 17, 2018 /EINPresswire.com/ — In July, pharmaceutical giant Bayer announced their plan to discontinue the production and distribution of their birth control implant known as Essure. Essure is the only permanent form of non-surgical birth control available for women in the United States. However, this device has led many women to develop painful, and sometimes fatal, side effects.

The office of Mike Brandner Injury Attorneys is now accepting and reviewing claims against Essure birth control implants and the serious side effects resulting from having the device implanted. If you or someone you love has been injured as a result of this implant, please don’t hesitate to reach out to us. We will aggressively pursue your due compensation and fight to ensure that you receive justice. Contact our team for a free consult. Further, we will not ask for fees from you unless we are successful in your lawsuit. Our network of partners spans the nation so you can trust that no matter where you live, we’ll have you covered.

Essure Birth Control Implant

The Essure implant itself is made up of polyester fibers surrounded by a flexible nickel alloy coil. The device is then implanted into the fallopian tubes in an non-surgical, out-patient procedure, where scar tissue will build around the implant over time. This scar tissue blocks the path released eggs take from the ovaries to reach the uterus, thus preventing pregnancy. This procedure is known as hysteroscopic sterilization.

The US Food and Drug Administration (FDA) originally approved Essure in 2002. However, reports of serious side effects stemming from use of the implant led to the FDA making some changes. In 2016, the FDA began to require a “black box” warning label on all packaging of Essure, and placed further restrictions on the distribution of the product two years later.

Bayer still firmly believes that their product is safe for public use. As a result, they will do all they can to ensure that you are not compensated for injuries you sustained from use of Essure. Personal injury lawyer Mike Brandner knows, “pharmaceutical giants like Bayer are notorious for being extremely resistant to admitting fault and compensating those their products have injured. We don’t want to let them push you around. Our team wants to help you get the justice you deserve.”

More About Mike Brandner Injury Attorneys

Mike Brandner Injury Attorneys has successfully represented victims from a variety of backgrounds with lawsuits against large insurance companies, Fortune 500 companies, large corporations, condominium associations, labor unions, and more involving injuries related to traffic accidents, defective products, workplace accidents, maritime accidents, railroad accidents (FELA), and other accidents. Find out more about Mike Brander and his team of Louisiana personal injury attorneys online at branderlawfirm.com or by calling (504) 345-1111. You can also interact with the law firm by connecting with them on Twitter and Facebook.

Mike Brandner
Mike Brandner Injury Attorneys
(504) 345-1111
email us here


Source: EIN Presswire

Global Neuroprosthetics Market Research and Forecast 2018-2023

Global Neuroprosthetics Industry Research Report

Orion market Research | OMR Global

Global Neuroprosthetics Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Rising prevalence of neural diseases is the major driver for the growth of neuroprosthetics market.”

— OMR Analyst

INDORE, INDIA, August 17, 2018 /EINPresswire.com/ — According to OMR analysis, the global neuroprosthetics market is expected to grow at a significant rate during (2018-2023). The global neuroprosthetics market has been showing significant growth due to increasing prevalence of neural diseases and rising inclination towards spinal cord injury treatment. The global neuroprosthetics market is segmented on the basis type, treatment technique, application and geography. The report provides detailed and insightful chapters on market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market share analysis, competitive landscape, company profiling, market segmentation, geographical analysis, analyst insights.

Full report of global neuroprosthetics market is available at: https://www.omrglobal.com/industry-reports/neuroprosthetics-market/

“The global neuroprosthetics market on the basis of treatment technique is bifurcated as deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS) and spinal cord stimulation (SCS). DBS as a treatment has been approved by the FDA in 1997 for essential tremor and Parkinson's disease; in 2003 for dystonia; and for OCD in 2009. DBS system is being used in research studies for the treatment of chronic pain, Post-Traumatic Stress Disorder (PTSD). It has also been used for the treatment of various affective disorders such as major depression. DBS is a neurosurgical process that involves implantation of a medical device, neurostimulator or sometimes called brain pacemaker. This device sends electrical impulses to specific targets in the brain through implanted electrodes for treating the movement and neuropsychiatric disorders.”

The market on the basis of geography is divided among four major regions – North America, APAC, Europe, and Rest of the world. North America is considered to be dominating market. The market is expected to grow at a stable CAGR. North American market is driven by high prevalence of spinal cord injuries, ability of people to afford the expensive treatment and research and development in artificial senses. Asia Pacific market is expected to have the highest CAGR amongst all regions for the forecast period of 2018-2023. APAC market is driven by increasing disposable income and improved healthcare facilities in the Asian countries.

The report covers:
· Comprehensive research methodology of Neuroprosthetics Market
· This report also includes detailed and extensive market overview with key analyst insights.
· An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
· Analysis of regional regulations and other government policies impacting the Neuroprosthetics Market
· Insights about market determinants which are stimulating the Neuroprosthetics Market
· Detailed and extensive market segments with regional distribution of forecasted revenues.
· Extensive profiles and recent developments of market players.

For related reports please visit: https://www.omrglobal.com/reports-category/medical-devices/

About Orion Market Research
Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here

Global Neuroprosthetics Market Report


Source: EIN Presswire

Global Melanoma Cancer Market Research and Forecast 2018-2023

Global Melanoma Cancer Market Research By OMR

Orion Market research

Global Melanoma Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Rising incidences of melanoma will boost the global melanoma market”

— OMR Analyst

INDORE, INDIA, August 17, 2018 /EINPresswire.com/ — Orion Market Research (OMR) recently published a market research report on global melanoma market. It is estimated that the market is augmenting with a noteworthy growth rate during the forecast period 2018-2023. The market is augmenting due to increasing incidence of melanoma globally and rising ozone layer depletion due to global warming are the major factor driving the market during forecast period. The global melanoma market is segmented on the basis of cancer type, therapy and by diagnosis method. The report provides detailed and insightful chapters which includes market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market insights, company profiling, market segmentation, geographical analysis, analyst insights of the market.

Browse Full Report At: https://www.omrglobal.com/industry-reports/melanoma-cancer-market/

Melanoma develops due to unrepaired DNA damage to skin cells due to expose of skin to ultraviolet radiation. The exposer triggers mutation which causes skin cells to multiply rapidly and form malignant tumors. Although it is not the most common skin cancers, however, it causes most deaths. As per American Medical Association, the total incident cases of the melanoma in 2015 were more than 352,000 with a growth of 56% as compared to 2005 globally. It has high prevalence rate in the developed economies such as the US, Germany, France, Italy, Australia and Canada. Australia has significant high prevalence of melanoma as it was the 4th leading cancer in 2015 in the region. In Germany it is the 5th leading cancer and 6th leading cancer in the UK, & the US. As per Skin Cancer Foundation, more than 87,000 new cases related to melanoma were registered in the US in 2017 and estimated mortality due to melanoma is near to 9,700. In Australia, as per Cancer Australia, estimated cases of the melanoma in 2018 are about 14,300 and expected mortality is near to 1,900. It is expected that melanoma has over 10% share to all new cancer cases in 2018. Similarly, as per Cancer Research UK 16,000 new cases are registered in the UK in 2015.

The major factor for the high incidence of the melanoma is the exposer of the people in the UV rays specially. The sun contains harmful Ultraviolet rays (UV-rays) which is the chief cause of melanoma. It is absorbed by ozone layer, present in the stratosphere. The ozone layer is depleting due to increasing pollution and increasing emission of greenhouse gases such as CFC used in refrigeration, insulation and spray-can propellants and methyl bromide. Due to UV radiation a pigment can be caused as skin cancer. As per UK ozone-hole organization a 10% global loss of ozone may lead to a 26% increase in the incidence of skin cancers among fair skinned people. Hence, depletion of ozone layer is also playing a vital role in increasing the total melanoma cases, globally. Due to which, a significant market for melanoma diagnosis and treatment can be expected during the forecast period.

The report covers:
Comprehensive research methodology of Global Melanoma Market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the
Global Melanoma Market.
Insights about market determinants which are stimulating the Global Melanoma Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

For Related Reports: https://www.omrglobal.com/reports-category/healthcare/

About orion market research
Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here

Global Melanoma Cancer Market Research


Source: EIN Presswire

SGB in Full Swing for Nov. 8 Inaugural Fundraising Golf Tournament

Walking the Gleneagles Course for Nov. 8

SoFlo's Signature Gives Back to Elevate UnLIMBited Foundation's Tommy Fund and Upward On Veterans Outreach

We are the Change We Wish to See in this World.”

— Wendy Pressner

BOCA RATON, FLORIDA, UNITED STATES, August 17, 2018 /EINPresswire.com/ — BOCA RATON, FL— Signature Gives Back (SGB) has announced in-depth info about its Inaugural Fundraising Golf Tournament slated for Thursday, November 8, 2018 at the prestigious Gleneagles Country Club in Delray Beach, FL.
Registration starts at 11:30 a.m., with shotgun at 1 p.m., and the tournament concludes with a 5 p.m. networking cocktail reception in The Glen Bar. The event is open to the public and will raise funds to champion UnLIMBited Foundation, Signature Gives Back, and Upward On.

SGB’s golf tournament will feature the notable talents of one-arm, 7-year-old golf prodigy, Tommy Morrissey, who’s appeared on TV’s “Ellen DeGeneres Show” and “Little Big Shots” (starring entertainer Steve Harvey). National and international press coverage for the tournament is strongly expected, and early registration is recommended for this greatly anticipated event.

UnLIMBited Foundation provides critical financial assistance to those families needing support as their child undergoes extensive, advanced limb-saving surgery and rehabilitation through the world-renowned Paley Institute in West Palm Beach. Tommy’s mother, Marcia Morrissey, is serving as Honorary Chair. Chairs of Event are: Ivan Benjamin, Jr., Robert Gleichenhaus, Melainey Gunning and Wendy Pressner. Chairs of Sponsors/Auction are Sung Knowles and Rachel Gleichenhaus.
Tommy Morrissey is all business when it comes to his golf game. Representing “The Tommy Fund” for UnLIMBited Foundation, he will lead the way in a One-Arm Challenge with golfers from Signature Real Estate Companies and beyond.

SGB organizes a myriad of volunteer and fundraising events, supporting an array of charities and local South Florida causes. It is a volunteer-driven organization utilizing the talents of its participating REALTORS® and management team from The Signature Real Estate Companies, headquartered in Boca Raton, FL.

Upward On assists veterans and their families transition from military service to civilian life and inspires continuous growth through mentorship and transition-resource facilitation.

For sponsorship opportunities and registration as a golf participant or cocktail reception guest, visit: Golf.SignatureGivesBack.com, email: Golf@SignatureGivesBack.com, or call: 561.371.1107, and “Be the Change You Wish to See in this World.”

Dana Levy, REALTOR®, MHS, CRC, MRP
The Signature Real Estate Companies
5618091125
email us here

Tommy in Action


Source: EIN Presswire

Global Minimally Invasive Surgical Instruments Market Research and Forecast 2018-2023

Minimally Invasive Surgical Instruments Market

Global Industry Research By OMR

Global Minimally Invasive Surgical Instruments Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Rising prevalence of lifestyle-oriented diseases & technological innovations is fuelling minimally invasive surgical instruments market.”

— OMR Analyst

INDORE, INDIA, August 17, 2018 /EINPresswire.com/ — According to OMR analysis the global minimally invasive surgical instruments market is growing significantly during the forecast period 2018-2023. The global minimally invasive surgical instruments market has been segmented on the basis of product, technology and applications. The report provides detailed & insightful chapters which includes market overview, key findings, strategic recommendations, market estimations, device regulations, market determinants, key company analysis, market insights, company profiling, market segmentation, and geographical analysis.

Increasing prevalence of lifestyle oriented diseases such as CVD is driving the demand for minimally invasive surgical instruments market. According to WHO, CVD is the major cause of death globally and more people lost their lives due to CVD than any other cause. CVD has accounted around 17.7 million deaths in 2015. It represents 31% of all global deaths. Among these deaths, 7.4 million were occurred due to heart disease and 6.7 million due to stroke. More than three quarters of CVD deaths witnessed in low and middle income countries. Such prevalence of CVD leads the demand for minimally invasive surgical instruments for the treatment of patients with CVD. The advantage of minimally invasive cardiac surgery is extensive than the open-heart surgery. Open heart surgery requires 6-8 incision in the chest and might be needed temporary placement of a pacemaker to regulate patient’s heartbeat.

Full report of Global Minimally Invasive Surgical Instruments Market is available at: https://www.omrglobal.com/industry-reports/minimally-invasive-surgical-instruments-market/

However, the minimally invasive cardiac surgery can be performed using robotic and involves one or more tiny incisions between ribs. Thereafter, surgical instruments coupled with small camera are placed through the incision. Then, the surgical tools are linked to the arms of robotics that is controlled by the surgeon with a computerized device. The instruments used in minimally invasive cardiac surgery include retractors, forceps, cutter instruments, stents and sutures. Additionally, minimally invasive cardiac surgery methods are used in atrial septal defect closure, aortic valve replacement, mitral valve repair and maze procedures to treat atrial fibrillation. There are several benefits associated with minimally invasive cardiac surgery as smaller incisions are involved in it. Moreover, it includes shorter hospital stays (generally 2-5 days), minimal risk of bleeding and infection, less scarring and pain and shorter recovery time.

The global minimally invasive surgical instruments market is segmented into product, technology and applications. Based on technology, robotic-assisted methods are gaining significant popularity and technological innovations have been observed which is increasing the effectiveness of this technology. Robot-assisted methods are used in several specialties, including head and neck surgery, urology, gynecologic oncology, cardiothoracic and gastrointestinal. For example, In Dec 2016, Cambridge consultants developed Axsis robot to overcome challenges of current surgical robots, including the inability to act with extremely fragile and detailed tissues and large size of the robots. Like da Vinci surgical systems, Axsis doesn’t use rigid and long instruments, however, rely on flexible components results in the smaller size of the robot. Axsis is designed to perform cataract surgery. It has flexible, tiny and worm-like arms and controlled with a joystick that offers tactile feedback. Additionally, it has an internal algorithm autopilot that keeps the surgeons who are guiding it to not make dumb mistakes. The system assimilates with real-time 3D imaging that provides an advanced level of robotic assistance. Posterior Capsule (PC) tears are the most common serious complications in the UK. Axsis can reduce complications rates and develop patient outcomes.

The report covers:
Comprehensive research methodology of Global MIS Instruments Market.
This report also includes detailed and extensive market overview with Analyst insights & key market trends.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global MIS Instruments Market.
Insights about market determinants which are stimulating the Global MIS Instruments Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

For related reports please visit: https://www.omrglobal.com/reports-category/medical-devices/

About orion market research
Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here

Global Minimally Invasive Surgical Instruments Market Research Report


Source: EIN Presswire

Renée Fleming, Opera Great and Multi-Grammy Winner, Visits Wartburg

Renée Fleming with Registrants

LtoR: Renée Fleming, David J. Gentner, Dr. Connie Tomaino

MT. VERNON, NEW YORK, USA, August 16, 2018 /EINPresswire.com/ — Contact: Angela Ciminello
914-513-5179; aciminello@wartburg.org

Opera Great and Multi–Grammy Winner, Renée Fleming visits Wartburg

Mount Vernon, NY, August 13, 2018 – Wartburg, Westchester’s premier provider of comprehensive residential and healthcare services for seniors, hosted the Tony-nominated Broadway star of Carousel, Renée Fleming. Wartburg President & CEO, David J. Gentner, the Institute for Music and Neurologic Function Executive Director Dr. Concetta Tomaino, Wartburg board member, Ulrich J. Rosa, and other senior staff met with Ms. Fleming in an effort to highlight the importance of music and arts on Wartburg’s campus.

“It was a joy to visit Wartburg – with the natural beauty of the campus and comprehensive care, its residents must feel at ease and at home.” Fleming said. “Understanding that integrating the arts greatly enhances quality of life and provides many cognitive and social benefits is especially powerful. I look forward to following the groundbreaking work of the Institute of Music and Neurologic Function, led by Dr. Connie Tomaino, as it continues the scientific exploration of the power of music therapy to awaken, stimulate, and heal the brain.”

While at Wartburg, Ms. Fleming visited the Adult Day Services program and was greeted by registrants singing as piano music filled the room. Additionally, she learned about the innovative music therapy services offered by the Institute for Music and Neurologic Function (IMNF) and Wartburg’s award-winning, internationally recognized arts-based therapy program, Creative Aging & Lifelong Learning. She also visited Wartburg’s Outpatient Center to hear about innovative programs using music to improve mobility and speech impairments.

IMNF Executive Director and Co-Founder, Dr. Concetta M. Tomaino said, “It was an honor to have Ms. Fleming visit IMNF at its new home at Wartburg. We are so grateful for her advocacy of the importance of music and brain health and happy she was able to see our work first hand.”

Ms. Fleming is a world renowned Soprano and four-time Grammy Award winner. In 2013, then President Obama awarded her the National Medal of Arts, America's highest honor for an individual artist. Ms. Fleming is a longtime advocate for the transformative power of music, including its therapeutic uses for individuals with neurologic issues. In 2016, she initiated a partnership between the National Institute for Health and the John F. Kennedy Center for the Performing Arts focusing on the intersections of music and the brain and is a spokesperson for the American Music Therapy Association.

Wartburg President, David J. Gentner shared, “Wow, what a thrill to welcome a legend to the campus. Ms. Fleming’s beliefs about the value of music and the arts in society are well documented so we were delighted that she would find the time to visit with Dr. Tomaino.”
Fleming’s visit ended with President Gentner reading a proclamation making Ms. Fleming an honorary member of the Wartburg family.

Wartburg
Wartburg, located in Westchester County, NY, offers integrated, comprehensive senior residential and healthcare services. Unlike conventional retirement communities, Wartburg provides a wide range of services to both residents living on its beautiful 34-acre campus and people in their own homes. From independent, assisted living and award-winning nursing home care to inpatient/outpatient rehabilitation, home care and adult day care services, its continuing care approach has earned Wartburg a trusted reputation in Westchester. Wartburg also provides caregiver support at every stage with an array of options to find the level of care that considers the whole family. Most recently, Wartburg was named one of the "Best Nursing Homes in New York State" by U.S. News & World Report for the eighth consecutive year in 2018. In addition, Wartburg received the 2016 Eli Pick Facility Leadership Award from the American College of Health Care Administrators and the 2015 Legacy Award from the Westchester County Chapter of the Links

Wartburg Website Homepage: www.wartburg.org/
Wartburg Facebook Page: www.facebook.com/thewartburg/
Wartburg Twitter Page: www.twitter.com/thewartburg
YouTube Page: www.youtube.com/wartburgny

Angela Ciminello, Vice President of Development & Marketing
Wartburg
914-513-5179
email us here


Source: EIN Presswire

California Verdict Sets Significant Precedent for RoundUp Lawsuits

A California court verdict has set a massive precedent for the cases brought against Monsanto. Lerner and Rowe Injury Attorneys is currently accepting cases.

Mega corporations like Monsanto are notoriously intimidating to go against on your own. We want to make sure that you don’t get bullied into submission. They have to be held accountable.”

— Kevin Rowe

PHOENIX, ARIZONA, US, August 16, 2018 /EINPresswire.com/ — At the end of last week, a California court reached a verdict that many believe has set a massive precedent of expectations for the continued wave of cases brought against Monsanto and it’s weed-killing product RoundUp. After deliberating for three days, a jury concluded that Dewayne Johnson’s use of RoundUp as a regular part of his former job as a school groundskeeper was responsible for the terminal cancer he developed. The court ordered Monsanto, the company that manufactures and distributes RoundUp, to pay Johnson $39 million for his suffering and a further $250 million in punitive damages. Our team at Lerner and Rowe Injury Attorneys is currently accepting and reviewing cases to represent you if you or a loved one was injured at the hands of Monsanto and RoundUp.

Links to Cancer

RoundUp has been thought to cause cancer, specifically non-Hodgkin's lymphoma, in a number of its users for years. Despite these claims, Monsanto has stood by and defended RoundUp’s safety for continued use. The company frequently cites studies that claim that glyphosate, the main weed-killing ingredient in RoundUp, isn’t immediately carcinogenic to humans. Yet, lawsuits against the product appear to focus more on the negative effects of the entire chemical solution, as opposed to the single ingredient.

Dewayne Johnson’s case was the first to reach trial, expedited by the terminal nature of his disease, and has set the tone for the remaining cases against the company. According to CNN, more than 800 patients are currently in the process of bringing cases against Monsanto that claim Roundup led to their developing cancer.

Monsanto is Standing by Their Product

Even after this monumental verdict, Monsanto continues to defend the safety of RoundUp and plans to continue to fight against these allegations. Following the decision, Monsanto’s Vice President Scott Partridge released a statement saying, “We will appeal this decision and continue to vigorously defend this product, which has a 40-year history of safe use and continues to be a vital, effective and safe tool for farmers and others."

If you, or someone you care about, were a user of RoundUp and developed non-Hodgkin’s lymphoma, or other cancers, as a result, please don’t hesitate to reach out to Lerner and Rowe Injury Attorneys. We will work together with you to form a plan of action to fight for your justly due compensation. Let us do the heavy lifting for you. “Mega corporations like Monsanto are notoriously intimidating to go against on your own. We want to make sure that you don’t get bullied into submission by a company that is trying to cover up their gross negligence. They have to be held accountable,” says personal injury attorney Kevin Rowe.

More about Lerner and Rowe

For additional information about Lerner and Rowe’s Phoenix personal injury attorneys call (602) 977-1900. To learn more about the criminal defense and bankruptcy legal services offered by their partner law firm Lerner and Rowe Law Group, visit lernerandrowelawgroup.com or call (602) 667-7777. Need help filing an application or appeal for Social Security benefits? Contact the law firms other legal partners at Social Security Disability Advocates by calling (602) 952-3200 or online at socialsecuritydisabilityadvocatesusa.com.

To connect with the law firm socially, follow Lerner and Rowe on Twitter, or become a fan of their Facebook page. Also visit lernerandrowegivesback.com to learn more about the community services that the lawyers and legal support team of Lerner and Rowe actively support.

Jim Rolshouse
Lerner & Rowe Injury Attorneys
952-200-3129
email us here


Source: EIN Presswire

The New End of Life Doula Profession Merges with Health Care in Historic NYC Event

PDI Founders With NHPCO President Edo Banach

Leaders in The End of Life Doula Movement Come Together and Hold Inaugural Event in New York City September 27th – 30th

NEW YORK, NY, UNITED STATES, August 16, 2018 /EINPresswire.com/ — Hosted by Professional Doula International – a collaboration between Patty Burgess of Teaching Transitions/Doing Death Differently, Deanna Cochran RN of Quality of Life Care, and Suzanne O’Brien RN of The International Doulagivers Institute. This is an event especially for hospice, palliative care, comfort care, senior care and end-of-life doulas (or those who want to be!) to learn how to work within healthcare organizations who are beginning to embrace the utilization of doulas in their agencies. This weekend event will offer the NPEC Certification (National Professional End-of-Life Doula Certification) which is a specific healthcare focus, and it offers nursing CEs. The time has come for palliative and EOL doulas to take their rightful place alongside, and supporting mainstream healthcare.

(The “silver tsunami” in healthcare is upon us. The number of patients aging and needing palliative and end-of-life care is increasing at an alarming rate. Hospices are the only option for end-of-life care in this country other than personal caregivers. There are huge time and service limitations for hospices to serve this need.

Doulas are the bridge between the patient/family and healthcare agencies. EOL Doulas can serve in capacities that agencies cannot staff for at this time.

NATIONAL INITIATIVES ARE NOW IN PLACE
The newly formed NHPCO End of Life Doula Council and The National End of Life Doula Alliance (NEDA) have been created to establish this new progressive profession and also set the highest level of standards and scope of practice.

This training, led by US EOL doula trainers is designed to offer the highest level, and most relevant, current best practices for this doula role. You can use the 'NPEC' designation upon the successful completion of your NPEC Certification Weekend.

ABOUT PDI FOUNDERS: Deanna Cochran RN, Suzanne B. O'Brien RN , and Patty Burgess are all founding members of NHPCO'S End of Life Doula Council and Founding members of NEDA National End of Life Doula Alliance. Together, they bring more than 50 years of experience to the NPEC Training.

The NPEC conference is approved for 12 CE hours (nursing) and is co-provided by Home Care Institute, LLC. HCI is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Suzanne B. O'Brien RN
Professional Doula International
845-337-0389
email us here


Source: EIN Presswire

Global Pharmacy Benefit Management Market (PBM) 2018 Analysis and Forecast to 2023 Research Report

MarketResearchNest.com adds “Global Pharmacy Benefit Management (PBM) Market 2018 by Manufacturers Regions Type and Application to 2023” report to its database.

PUNE, INDIA, August 16, 2018 /EINPresswire.com/ — MarketResearchNest.com adds “Global Pharmacy Benefit Management (PBM) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” new reports to its research database. The report spread across 133 pages with tables and figures in it.

Pharmacy benefit manager (PBM) is a third-party administrator (TPA) of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans.

This report focuses on the Pharmacy Benefit Management (PBM) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Pharmacy Benefit Management (PBM) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Order a purchase report copy of at https://www.marketresearchnest.com/report/purchase/403080 .

Market Segment by Manufacturers, this report covers
CVS Health (CVS)
Express Scripts
OptumRx (UnitedHealth)
Humana Pharmacy Solutions
Prime Therapeutics
Medimpact Healthcare
Magellan Health
BC/BS
Vidalink
Sea Rainbow
Cachet

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Inquire before Buying at https://www.marketresearchnest.com/report/enquirybuy/403080 .

Market Segment by Type, covers
commercial health plans
self-insured employer plans
Medicare Part D plans
Federal Employees Health Benefits Program
state government employee plans

Market Segment by Applications, can be divided into
Mail-order Pharmacy Services
Non-mail Pharmacy Services

There are 15 Chapters to deeply display the global Pharmacy Benefit Management (PBM) market.
Chapter 1, to describe Pharmacy Benefit Management (PBM) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Pharmacy Benefit Management (PBM), with sales, revenue, and price of Pharmacy Benefit Management (PBM), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Pharmacy Benefit Management (PBM), for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Pharmacy Benefit Management (PBM) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Pharmacy Benefit Management (PBM) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Get a Report Details at https://www.marketresearchnest.com/Global-Pharmacy-Benefit-Management-PBM-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html .

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us
Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

Mr Jeet
Market Research Nest
1-240-284-8070
email us here


Source: EIN Presswire

PetVivo Holdings, Inc. Moves Manufacturing Facility, Creates Research and Development Laboratory.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

MINNEPOLIS, MINNESOTA, USA, August 16, 2018 /EINPresswire.com/ — PETVIVO HOLDINGS, INC. MOVES AND EXPANDS MANUFACTURING FACILITY. CREATES RESEARCH AND DEVELOPMENT LAB

(OTCMARKETS: PETV), PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is pleased to announce the moving of its manufacturing facility and the creation of a research and development lab.

In an effort to expand manufacturing and create a research and development facility, Petvivo, Inc. moved from Elite Solutions in Rochester, Minnesota to the home of CytoMedical Design Group LLC (cmdg) in St. Paul, Minnesota. The location has far better access for Petvivo employees and eliminates the costs of hotels and mileage which the company has been absorbing sending and supporting staff from Minneapolis for weeks at a time to work in Rochester.

“We estimate that our cost of manufacturing will be reduced substantially. It is also time to address our plan to continue improving our product and initiate our research and development plans. Assistance for both manufacturing and research will be available from staff members of the cmdg group. Cmdg has additional clean rooms and square footage for our use “commented Wes Hayne, CEO of Petvivo Holdings, Inc.

The move was performed in one week, coordinated with three different moving companies. Each company specializing in specific equipment, with different degrees of sensitivity. The move is now complete, and production is expected to resume within the next three weeks. The new surroundings and extra space will help in building the efficiencies of the manufacturing process.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Wes Hayne
Petvivo Holdings Inc
962-405-6216
email us here


Source: EIN Presswire